Zoetis (ZTS) Other Non-Current Assets (2012 - 2026)
Zoetis' (ZTS) quarterly Other Non-Current Assets came in at $384.0 million in Q2 2026, up 43.82% year-over-year from $267.0 million in Q2 2025, and up 9.4% quarter-over-quarter from $351.0 million in Q1 2026.
Analysis
Zoetis (ZTS) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Other Non-Current Assets for 15 consecutive years, with $384.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Non-Current Assets rose 43.82% year-over-year to $384.0 million in Q2 2026; TTM through Jun 2026 was $384.0 million, a 43.82% increase from a year earlier, with the FY2025 full-year figure at $327.0 million, up 30.8% from the prior year.
- Other Non-Current Assets was $384.0 million for Q2 2026 at Zoetis, up from $351.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $384.0 million in Q2 2026 and troughed at $129.0 million in Q1 2022.
- A 5-year average of $238.5 million and a median of $229.5 million in 2024 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 88.44% in 2024 and decreased 18.1% in 2025, its largest moves.
- Over 5 years, Other Non-Current Assets stood at $147.0 million in 2022, then surged by 40.14% to $206.0 million in 2023, then gained by 21.36% to $250.0 million in 2024, then jumped by 30.8% to $327.0 million in 2025, then rose by 17.43% to $384.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $384.0 million (Q2 2026), $351.0 million (Q1 2026), and $327.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | 567.73 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | 384.00 Mn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 304.00 Mn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | 106.46 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | 31,658.00 |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | 988,922.10 |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 384.00 Mn |
| Mar 31, 2026 | 351.00 Mn |
| Dec 31, 2025 | 327.00 Mn |
| Sep 30, 2025 | 293.00 Mn |
| Jun 30, 2025 | 267.00 Mn |
| Mar 31, 2025 | 232.00 Mn |
| Dec 31, 2024 | 250.00 Mn |
| Sep 30, 2024 | 314.00 Mn |
| Jun 30, 2024 | 326.00 Mn |
| Mar 31, 2024 | 227.00 Mn |
| Dec 31, 2023 | 206.00 Mn |
| Sep 30, 2023 | 216.00 Mn |
| Jun 30, 2023 | 173.00 Mn |
| Mar 31, 2023 | 143.00 Mn |
| Dec 31, 2022 | 147.00 Mn |
| Sep 30, 2022 | 161.00 Mn |
| Jun 30, 2022 | 147.00 Mn |
| Mar 31, 2022 | 129.00 Mn |
| Dec 31, 2021 | 111.00 Mn |
| Sep 30, 2021 | 112.00 Mn |